Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint blockade therapies
Prior exposure to either ipilimumab or combined checkpoint blockade
Unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atricurium, cisatricurium, etc.)
Prior treatment with CD agonists or immune checkpoint blockade therapies;
Documented progression to prior therapies: a) Cohort A: Disease progression following prior immune checkpoint blockade therapy; b) Cohort B: Progression or intolerance to at least  prior lines of standard therapy for unresectable or metastatic CRC; c) Cohort C: Disease progression following prior immune checkpoint blockade therapy.
Cohort B only: prior exposure to any immune checkpoint blockade agent or any other immunomodulatory agent used for antineoplastic therapy for mCRC.
Prior checkpoint inhibitors/blockade in the last  months.
Failure to respond to standard of care checkpoint blockade therapy or previously responding patients who progress on checkpoint blockade therapy
Patients requiring beta blockade are disqualified from participating in this study
Prior use of agents for TNF-alpha blockade
Human immunodeficiency virus (HIV)-positive patients are ineligible due to the risks associated with immune checkpoint blockade
Prior treatment with CD agonists or immune checkpoint blockade therapies.
Has plans to receive cytotoxic chemotherapy, immune checkpoint inhibitors (eg CTLA- blockade), sipuleucel-T, radiopharmaceuticals, abiraterone or other experimental therapy during this study period
Prior treatment with clusters of differentiation (CD)  agonists or immune checkpoint blockade therapies, systemic immunostimulatory agents, or systemic immunosuppressive medications
Demonstration of progression while on androgen blockade
Patient receiving any investigational or experimental agents other than checkpoint blockade immunotherapy
Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint blockade therapies
Prior treatment with CD agonists or immune checkpoint blockade therapies
Prior treatment with CD agonists or other immune checkpoint blockade therapies, including anti-CTLA- therapeutic antibodies
Patients who are eligible to receive combined dual immune-checkpoint blockade therapy with ipilimumab and nivolumab, per referring oncologist